CliffBio
small molecule

VESICARE LS

SOLIFENACIN SUCCINATE

Loss of exclusivityMay 2031latest FDA-listed patent expiry
CompanyAstellas Pharma Us →View the full company profile on CliffBio

Drug detail

Brand nameVESICARE LS
Active ingredientSOLIFENACIN SUCCINATE
Strength1MG/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2020
Marketing statusDISCN

Listed patents

PatentExpiresType
9918970May 2031product

More from Astellas Pharma Us

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VESICARE LS patent cliff — loss of exclusivity May 2031 | CliffBio